Nancy Valente

5.3k total citations · 3 hit papers
12 papers, 2.6k citations indexed

About

Nancy Valente is a scholar working on Genetics, Pathology and Forensic Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Nancy Valente has authored 12 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Genetics, 7 papers in Pathology and Forensic Medicine and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Nancy Valente's work include Chronic Lymphocytic Leukemia Research (7 papers), Lymphoma Diagnosis and Treatment (7 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Nancy Valente is often cited by papers focused on Chronic Lymphocytic Leukemia Research (7 papers), Lymphoma Diagnosis and Treatment (7 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Nancy Valente collaborates with scholars based in United States, Switzerland and France. Nancy Valente's co-authors include Michael Wenger, Timothy M. Clay, H. Kim Lyerly, Alain Delcayre, Michael A. Morse, Amy Hobeika, Revati Shreeniwas, Jennifer Garst, Jean‐Bernard Le Pecq and Di‐Hwei Hsu and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Nancy Valente

12 papers receiving 2.5k citations

Hit Papers

A phase I study of dexosome immunotherapy in patients wit... 2005 2026 2012 2019 2005 2017 2017 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer
    2005 917 citations Michael A. Morse, Jennifer Garst et al. Journal of Translational Medicine profile →
  2. Emicizumab Prophylaxis in Hemophilia A with Inhibitors
    2017 759 citations Johannes Oldenburg, Johnny Mahlangu et al. New England Journal of Medicine profile →
  3. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
    2017 396 citations Gilles Salles, Martin Barrett et al. Advances in Therapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nancy Valente United States 9 1.0k 803 768 642 559 12 2.6k
Michael H. Tomasson United States 32 1.6k 1.6× 1.8k 2.3× 659 0.9× 486 0.8× 265 0.5× 116 3.5k
Abraham Avigdor Israel 32 969 0.9× 1.4k 1.8× 559 0.7× 755 1.2× 723 1.3× 139 3.7k
David Wu United States 21 516 0.5× 547 0.7× 289 0.4× 631 1.0× 556 1.0× 65 2.4k
Hendrik De Raeve Belgium 34 1.4k 1.4× 1.3k 1.6× 391 0.5× 366 0.6× 179 0.3× 91 2.9k
Sebastian Böttcher Germany 26 531 0.5× 957 1.2× 1.6k 2.1× 870 1.4× 1.5k 2.7× 80 2.8k
Yoshikane Kikushige Japan 25 887 0.9× 1.0k 1.3× 426 0.6× 1.1k 1.7× 256 0.5× 89 2.5k
Stephen P. Mulligan Australia 20 676 0.7× 264 0.3× 1.2k 1.5× 638 1.0× 889 1.6× 115 2.0k
Akiro Kimura Japan 25 815 0.8× 1.2k 1.5× 712 0.9× 332 0.5× 167 0.3× 93 2.3k
Toshiki Uchida Japan 26 617 0.6× 675 0.8× 414 0.5× 277 0.4× 591 1.1× 86 1.9k
Anwar N. Mohamed United States 21 1.0k 1.0× 1.5k 1.9× 636 0.8× 210 0.3× 374 0.7× 70 2.7k

Countries citing papers authored by Nancy Valente

Since Specialization
Citations

This map shows the geographic impact of Nancy Valente's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nancy Valente with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nancy Valente more than expected).

Fields of papers citing papers by Nancy Valente

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nancy Valente. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nancy Valente. The network helps show where Nancy Valente may publish in the future.

Co-authorship network of co-authors of Nancy Valente

This figure shows the co-authorship network connecting the top 25 collaborators of Nancy Valente. A scholar is included among the top collaborators of Nancy Valente based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nancy Valente. Nancy Valente is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Morcos, Peter N., et al.. (2019). Rituximab dosing in hematological malignancies: an old question, revisited. Cancer Chemotherapy and Pharmacology. 84(3). 661–666. 2 indexed citations
2.
Oldenburg, Johannes, Johnny Mahlangu, Benjamin Kim, et al.. (2017). Emicizumab Prophylaxis in Hemophilia A with Inhibitors. New England Journal of Medicine. 377(9). 809–818. 759 indexed citations breakdown →
3.
Salles, Gilles, Martin Barrett, Robin Foà, et al.. (2017). Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Advances in Therapy. 34(10). 2232–2273. 396 indexed citations breakdown →
4.
5.
Li, Jing, Jianguo Zhi, Michael Wenger, et al.. (2012). Population Pharmacokinetics of Rituximab in Patients With Chronic Lymphocytic Leukemia. The Journal of Clinical Pharmacology. 52(12). 1918–1926. 64 indexed citations
6.
Robak, Tadeusz, Anna Dmoszyńska, Philippe Solal‐Céligny, et al.. (2010). Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 28(10). 1756–1765. 358 indexed citations
7.
Li, Jing, Jianguo Zhi, Michael Wenger, Nancy Valente, & Jennifer Visich. (2009). Higher Doses of Rituximab May Be Required for Patients with CLL as Compared to NHL Based On Population Pharmacokinetic (PK) Modeling.. Blood. 114(22). 1742–1742. 3 indexed citations
8.
Hornberger, John, Carolina Reyes, Deborah P. Lubeck, & Nancy Valente. (2008). Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. Leukemia & lymphoma. 49(2). 227–236. 40 indexed citations
9.
10.
Li, Jing, Micha Levi, Nicolas Frey, et al.. (2007). Rituximab Exhibits a Long Half-Life Based on a Population Pharmacokinetic Analysis in Non-Hodgkin’s Lymphoma (NHL) Patients.. Blood. 110(11). 2371–2371. 19 indexed citations
11.
Morse, Michael A., Jennifer Garst, Takuya Osada, et al.. (2005). A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. Journal of Translational Medicine. 3(1). 9–9. 917 indexed citations breakdown →
12.
Leonard, J.P., JM Vose, John Radford, et al.. (2000). Iodine I 131 tositumomab for patients with low-grade or transformed low-grade NHL: Complete response data.. Blood. 96. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael H. Tomasson Breakdown of academic impact, for papers by Abraham Avigdor Breakdown of academic impact, for papers by David Wu Breakdown of academic impact, for papers by Hendrik De Raeve Breakdown of academic impact, for papers by Sebastian Böttcher Breakdown of academic impact, for papers by Yoshikane Kikushige Breakdown of academic impact, for papers by Stephen P. Mulligan Breakdown of academic impact, for papers by Akiro Kimura Breakdown of academic impact, for papers by Toshiki Uchida Breakdown of academic impact, for papers by Anwar N. Mohamed
Rankless by CCL
2026